$118 Million is the total value of DAFNA Capital Management LLC's 72 reported holdings in Q1 2017. The portfolio turnover from Q4 2016 to Q1 2017 was 34.3% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ATRC | Sell | ATRICURE INC | $9,708,000 | -4.4% | 506,946 | -2.3% | 8.21% | -8.0% |
| NXTM | Sell | NXSTAGE MEDICAL INC | $5,798,000 | -6.3% | 216,119 | -8.5% | 4.90% | -9.8% |
| SNSS | Sell | SUNESIS PHARMACEUTICALS INC | $3,557,000 | -13.3% | 867,529 | -23.5% | 3.01% | -16.6% |
| GLPG | Sell | GALAPAGOS NVspon adr | $3,048,000 | -28.1% | 35,359 | -46.5% | 2.58% | -30.8% |
| BGNE | Sell | BEIGENE LTDsponsored adr | $2,974,000 | -18.3% | 81,231 | -32.2% | 2.52% | -21.3% |
| PODD | Sell | INSULET CORP | $2,736,000 | -1.2% | 63,484 | -13.6% | 2.31% | -4.9% |
| NBIX | Sell | NEUROCRINE BIOSCIENCES INC | $2,533,000 | -0.9% | 58,508 | -11.4% | 2.14% | -4.6% |
| AERI | Sell | AERIE PHARMACEUTICALS INC | $2,121,000 | -43.0% | 46,770 | -52.5% | 1.79% | -45.2% |
| RDUS | Sell | RADIUS HEALTH INC | $1,886,000 | -7.9% | 48,809 | -9.4% | 1.60% | -11.3% |
| CARA | Sell | CARA THERAPEUTICS INC | $1,753,000 | -9.9% | 95,322 | -54.5% | 1.48% | -13.3% |
| IMMU | Sell | IMMUNOMEDICS INC | $1,634,000 | -20.4% | 252,574 | -54.9% | 1.38% | -23.4% |
| ADXS | Sell | ADVAXIS INC | $1,405,000 | +12.1% | 172,000 | -1.7% | 1.19% | +7.9% |
| XENE | Sell | XENON PHARMACEUTICALS INC | $1,358,000 | -65.7% | 339,614 | -33.9% | 1.15% | -67.0% |
| Sell | NEURODERM LTD | $994,000 | +18.1% | 37,438 | -1.3% | 0.84% | +13.6% | |
| DERM | Sell | DERMIRA INC | $955,000 | -68.1% | 28,000 | -71.7% | 0.81% | -69.3% |
| NVDQ | Sell | NOVADAQ TECHNOLOGIES INC | $747,000 | +3.5% | 95,841 | -5.9% | 0.63% | -0.3% |
| Sell | IRONWOOD PHARMACEUTICALS INCdbcv 2.250% 6/1 | $714,000 | +3.5% | 573,000 | -4.5% | 0.60% | -0.3% | |
| ZGNX | Sell | ZOGENIX INC | $649,000 | -28.4% | 59,778 | -19.8% | 0.55% | -31.0% |
| ASND | Sell | ASCENDIS PHARMAsponsored adr | $510,000 | -52.5% | 18,214 | -65.6% | 0.43% | -54.3% |
| EIGR | Sell | EIGER BIOPHARMACEUTICALS INC | $412,000 | -12.0% | 35,977 | -10.5% | 0.35% | -15.3% |
| ABEO | Sell | ABEONA THERAPEUTICS INC | $338,000 | -9.1% | 67,537 | -12.1% | 0.29% | -12.5% |
| MASI | Sell | MASIMO CORPORATION | $326,000 | -51.6% | 3,500 | -65.0% | 0.28% | -53.4% |
| PIRS | Sell | PIERIS PHARMACEUTICALS INC | $139,000 | -55.7% | 53,525 | -76.0% | 0.12% | -57.2% |
| CHEKW | Exit | CHECK CAP LTD*w exp 02/28/202 | $0 | – | -15,250 | -100.0% | -0.01% | – |
| GNVC | Exit | GENVEC INC | $0 | – | -9,580 | -100.0% | -0.03% | – |
| AVGR | Exit | AVINGER INC | $0 | – | -25,000 | -100.0% | -0.08% | – |
| SGYPQ | Exit | SYNERGY PHARMACEUTICALS | $0 | – | -34,000 | -100.0% | -0.18% | – |
| SBPH | Exit | SPRING BK PHARMACEUTICALS IN | $0 | – | -27,412 | -100.0% | -0.19% | – |
| Exit | ESSA PHARMA INC | $0 | – | -98,046 | -100.0% | -0.25% | – | |
| ABUS | Exit | ARBUTUS BIOPHARMA CORP | $0 | – | -234,000 | -100.0% | -0.50% | – |
| CNCE | Exit | CONCERT PHARMACEUTICALS INC | $0 | – | -66,968 | -100.0% | -0.60% | – |
| PTGX | Exit | PROTAGONIST THERAPEUTICS INC | $0 | – | -45,586 | -100.0% | -0.88% | – |
| DSCI | Exit | DERMA SCIENCES INC | $0 | – | -353,718 | -100.0% | -1.62% | – |
| TSRO | Exit | TESARO INC | $0 | – | -15,500 | -100.0% | -1.83% | – |
| CYTK | Exit | CYTOKINETICS INC | $0 | – | -210,306 | -100.0% | -2.24% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2017-05-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| STEREOTAXIS INC | 42 | Q3 2023 | 27.6% |
| ATRICURE INC | 42 | Q3 2023 | 11.4% |
| MASIMO CORPORATION | 42 | Q3 2023 | 1.8% |
| ASCENDIS PHARMA A S SPONSORED | 34 | Q3 2023 | 4.5% |
| AERIE PHARMACEUTICALS INC | 33 | Q3 2022 | 4.2% |
| GALAPAGOS NV-SPON ADR | 33 | Q3 2023 | 3.8% |
| XENON PHARMACEUTICALS INC | 33 | Q3 2023 | 3.6% |
| NEUROCRINE BIOSCIENCES INC | 32 | Q3 2023 | 2.9% |
| JOHNSON AND JOHNSON | 32 | Q1 2021 | 1.2% |
| ISHARES TR NASDQ BIOTECH | 30 | Q3 2023 | 4.0% |
View DAFNA Capital Management LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Stereotaxis, Inc. | March 08, 2018 | 13,680,554 | 23.4% |
| SUNESIS PHARMACEUTICALS INC | February 14, 2018 | 983,000 | 2.9% |
| SUNESIS PHARMACEUTICALS INC | February 14, 2017 | 1,133,583 | 5.4% |
| WINDTREE THERAPEUTICS INC /DE/ | February 14, 2017 | 208,333 | 2.4% |
| ANAVEX LIFE SCIENCES CORP.Sold out | February 16, 2016 | 0 | 0.0% |
| DISCOVERY LABORATORIES INC /DE/ | February 16, 2016 | 10,658,699 | 9.2% |
| PRECISION OPTICS CORPORATION, INC. | February 13, 2015 | 311,537 | 5.0% |
| TearLab Corp | February 14, 2013 | 939,239 | 3.2% |
| VIKING SYSTEMS INC | February 14, 2012 | 3,781,468 | 5.2% |
View DAFNA Capital Management LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| SC 13G/A | 2023-02-14 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
View DAFNA Capital Management LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.